These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 8575503)

  • 1. Urinary interleukin-1 alpha levels are increased by intravesical instillation with keyhole limpet hemocyanin in patients with superficial transitional cell carcinoma of the bladder.
    Jurincic-Winkler CD; Gallati H; Alvarez-Mon M; Sippel J; Carballido J; Klippel KF
    Eur Urol; 1995; 28(4):334-9. PubMed ID: 8575503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response to keyhole limpet hemocyanin (KLH) treatment in patients with superficial bladder carcinoma.
    Jurincic-Winkler CD; von der Kammer H; Beuth J; Scheit KH; Klippel KF
    Anticancer Res; 1996; 16(4A):2105-10. PubMed ID: 8712751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Topical immunotherapy (KLH) vs. chemotherapy (Ethoglucid) in prevention of recurrence of superficial bladder cancer. A prospective randomized study].
    Flamm J; Donner G; Bucher A; Höltl W; Albrecht W; Havelec L
    Urologe A; 1994 Mar; 33(2):138-43. PubMed ID: 8178408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistological findings in patients with superficial bladder carcinoma after intravesical instillation of keyhole limpet haemocyanin.
    Jurincic-Winkler C; Metz KA; Beuth J; Engelmann U; Klippel KF
    Br J Urol; 1995 Dec; 76(6):702-7. PubMed ID: 8535712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value.
    de Reijke TM; de Boer EC; Kurth KH; Schamhart DH
    J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG.
    Haaff EO; Catalona WJ; Ratliff TL
    J Urol; 1986 Oct; 136(4):970-4. PubMed ID: 3489840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent superficial transitional cell carcinoma of the bladder: adjuvant topical chemotherapy versus immunotherapy. A prospective randomized trial.
    Flamm J; Bucher A; Höltl W; Albrecht W
    J Urol; 1990 Aug; 144(2 Pt 1):260-3. PubMed ID: 2197428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
    J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary interleukin-2 monitoring during prolonged bacillus Calmette-Guerin treatment: can it predict the optimal number of instillations?
    de Reijke TM; De Boer EC; Kurth KH; Schamhart DH
    J Urol; 1999 Jan; 161(1):67-71. PubMed ID: 10037371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravesical instillation therapy with bacillus Calmette-Guérin for superficial bladder cancer: study of the mechanism of bacillus Calmette-Guérin immunotherapy.
    Shintani Y; Sawada Y; Inagaki T; Kohjimoto Y; Uekado Y; Shinka T
    Int J Urol; 2007 Feb; 14(2):140-6. PubMed ID: 17302571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary interleukin-8/creatinine level as a predictor of response to intravesical bacillus Calmette-Guerin therapy in bladder tumor patients.
    Rabinowitz R; Smith DS; Tiemann DD; Hudson MA
    J Urol; 1997 Nov; 158(5):1728-31; discussion 1731-2. PubMed ID: 9334588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of keyhole limpet hemocyanin (KLH) and bacillus Calmette-Guérin (BCG) instillation on carcinoma in situ of the urinary bladder.
    Jurincic-Winkler C; Metz KA; Beuth J; Sippel J; Klippel KF
    Anticancer Res; 1995; 15(6B):2771-6. PubMed ID: 8669862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Keyhole limpet hemocyanin for carcinoma in situ of the bladder: a long-term follow-up study.
    Jurincic-Winkler CD; Metz KA; Beuth J; Klippel KF
    Eur Urol; 2000; 37 Suppl 3():45-9. PubMed ID: 10828687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Intravesical prevention of recurrence of superficial urinary bladder cancer with BCG and KLH. A prospective randomized study].
    Kälble T; Möhring K; Ikinger U; Riedasch G; Staehler G
    Urologe A; 1991 Mar; 30(2):118-21. PubMed ID: 2058066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of murine bladder cancer with keyhole limpet hemocyanin (KLH).
    Lamm DL; DeHaven JI; Riggs DR; Ebert RF
    J Urol; 1993 Mar; 149(3):648-52. PubMed ID: 8437283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of local Bacillus Calmette-Guérin treatment in superficial bladder cancer relapsing under Keyhole-Limpet Hemocyanin immunotherapy.
    Jurincic-Winkler C; Engelmann U; Beuth J; Klippel KF
    Zentralbl Bakteriol; 1995 Oct; 282(4):409-15. PubMed ID: 9810664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Assessment of 8-hydroxy-2'-deoxyguanosine concentrations in bladder cancer patients treated with intravesical BCG instillation].
    Kaczmarek P; Błaszczyk J; Fijałkowski P; Sierakowska-Fijałek A; Niemirowicz J; Kasprzak A; Baj Z
    Pol Merkur Lekarski; 2005 Oct; 19(112):526-8. PubMed ID: 16379317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy.
    Böhle A; Nowc C; Ulmer AJ; Musehold J; Gerdes J; Hofstetter AG; Flad HD
    J Urol; 1990 Jul; 144(1):59-64. PubMed ID: 2193171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keyhole limpet hemocyanin immunotherapy of bladder cancer: laboratory and clinical studies.
    Lamm DL; Dehaven JI; Riggs DR
    Eur Urol; 2000; 37 Suppl 3():41-4. PubMed ID: 10828686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer.
    De Boer EC; De Jong WH; Steerenberg PA; Aarden LA; Tetteroo E; De Groot ER; Van der Meijden AP; Vegt PD; Debruyne FM; Ruitenberg EJ
    Cancer Immunol Immunother; 1992; 34(5):306-12. PubMed ID: 1540977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.